- Policy
- Abbott accused of sponsoring academic society too often
- by Lee, Jeong-Hwan Oct 7, 2020 06:08am
- Global pharmaceutical and medical device company Abbott has been accused of providing questionable financial benefit to healthcare providers that exceeded the legal amount stipulated in the ‘Korean Sunshine Act.’ Apparently for a year, Abbott has sponsored Korean Society of Interventional Cardiology (KSIC) an approximate total of 250 mi
- Company
- Next-gen flu drug Xofluza green lit in general hospitals
- by Eo, Yun-Ho Oct 6, 2020 06:25am
- The next generation influenza treatment ‘Xofluza (baloxavir)’ has been passed by major general hospitals for prescription. According to the related industry source, the Drug Committees at the ‘Big Five’ general hospitals like Seoul National University Hospital and Seoul St. Mary's Hospital green lit Xofluza, while the rest of the Big
- Company
- Mundipharma Korea appoints Hun Choi as the new CEO
- by An, Kyung-Jin Oct 6, 2020 06:24am
- Mundipharma announced on the 5th that it had appointed Hun Choi (46 yrs old), Managing Director, as the new CEO as of October 1. He graduated from Korea University Department of Chemistry and entered the pharmaceutical industry when he joined Novartis Korea in 2001. He served as a brand manager and sales manager, starting with a salespers
- Policy
- Mishandled flu vaccines' recognition was announced in 10 hr
- by Lee, Jeong-Hwan Oct 6, 2020 06:24am
- Criticism was raised that the KDCA announced the suspension of vaccination after about 10 hours of being aware of the flu vaccine exposure to room temperature, causing damage to the public. The KDCA announced to domestic medical institutions that Shinsung Pharm’s vaccines would be halted at 11 pm on the 21st of last month, and the recogni
- Company
- Samsung Pharm won second trial with Samsung Electronics
- by Kim, Jin-Gu Oct 6, 2020 06:24am
- Samsung Pharm won the second round of the trademark dispute with Samsung Electronics over the name of 'Samsung'. Like the first trial, the second trial court admitted that Samsung Pharm had used the name Samsung for a longer time. The Patent Court of Korea ruled against the plaintiff in a lawsuit for invalidation of trademark registration
- Policy
- Additional evidences asked for 3 patients using Spinraza
- by Lee, Hye-Kyung Oct 6, 2020 06:23am
- The South Korean health authority has asked three preliminary approval applicants seeking to use spinal muscular atropy (SMA) treatment Spinraza with coverage to submit supplementary evidences. After the initial approval on reimbursed use of Spinraza, the applicant has to hand in monitoring report every four months before administering t
- Company
- Daewoong promotes the development of injectable hair loss tx
- by Nho, Byung Chul Oct 6, 2020 06:23am
- Daewoong is developing long-lasting hair loss treatments for male in earnest through open innovation that introduces promising external technologies. Daewoong (CEO Seng-Ho Jeon) signed a joint development contract with Inventage lab (CEO Ju Hee Kim), a drug delivery system platform venture company, on the 25th, and is conducting joint re
- Policy
- Daewoong's DWP16001, approved for Phase III clinical trial
- by Lee, Tak-Sun Oct 5, 2020 06:22am
- The SGLT-2 diabetes treatment drug being developed by Daewoong is entering phase III of clinical trial. This drug is expected to become the first domestic SGLT-2 diabetes drug if it obtains product approval. On the 29th of last month, the MFDS approved phase III clinical trial plan for Daewoong's new drug candidate 'DWP16001'. DWP16001
- Policy
- Health vice-minister answers questions on MOHW drug pricing
- by Kim, Jung-Ju Oct 5, 2020 06:21am
- Kang Do-tae (Master’s degree in Public Administration at Seoul National University) has been appointed as a first second vice-minister of Ministry of Health and Welfare (MOHW) to lead the health sector of the ministry amid COVID-19. And during an interview on him, the vice-minister expressed his commitment to not only focus on the infectious di
- Policy
- Off-label coverage on Cellcept and Mabthera expanded
- by Kim, Jung-Ju Oct 5, 2020 06:21am
- From next month, the off-label reimbursement would be expanded on Roche Korea’ immunosuppressant Cellcept Capsule (mycophenolate mofetil) and chronic lymphocytic leukemia and rheumatoid arthritis treatment Mabthera injection (rituximab). Lilly Korea’s psoriatic arthritis and ankylsoing spondylitis treatment Taltz Prefilled Syringe Inj
